BACKGROUND Although ablative fractional laser is the gold standard for acne scars, evidence is still lacking for other types of scars.
S
cars are a common phenomenon as they develop after skin injury in patients of all ages. Although most scars do not pose a health risk, they can be highly disfiguring, resulting in decreased quality of life. 1, 2 Also, pruritus, pain, and functional impairment do occur in certain cases. [3] [4] [5] Various therapies have been proposed in the treatment of different scar types, such as corticosteroids, 5-fluorouracil, bleomycin, silicone gel sheeting, pressure therapy, radiation, cryotherapy, and surgery. 6, 7 However, little evidence on the efficacy is available because of a lack of (randomized) controlled trials, and outcomes are usually disappointing.
Since the introduction of lasers in dermatology, many studies have been performed showing lasers to be effective in the treatment of scars. [6] [7] [8] [9] [10] [11] In the treatment of hypertrophic scars, most evidence is available for pulsed dye laser therapy, but also nonablative fractional lasers have shown efficacy. [12] [13] [14] [15] For atrophic acne scars, multiple randomized controlled studies have shown the ablative fractional carbon dioxide (CO 2 ) laser to be effective. [16] [17] [18] For the treatment of nonacne scars, evidence for ablative fractional laser therapy (AFLT) is lacking. 12 The aim of this study was to assess the efficacy and safety of ablative fractional 10,600-nm CO 2 laser therapy in the treatment of various types of scars. The Inclusion criteria were patients aged 18 years and older, Fitzpatrick skin Types I to IV, scars existing at least 1 year and allowing demarcation of 2 similar test regions of 2 · 2 cm, and willingness and ability to comply with the requirements of the protocol. Exclusion criteria were keloidal scars, suspected allergy to lidocaine, use of isotretinoin in the past 6 months, pregnancy or lactation, concomitant skin disease at the site of treatment, high exposure to sunlight or UV light, and patients not considered to be able to follow the treatment protocol. Previous scar treatment was not an exclusion criterion. A herpes simplex infection, formation of blisters larger than 3 mm, and clinical deterioration of the treated scar as a result of the treatment were also exclusion criteria.
Intervention
The study was a prospective single (observer) blinded randomized controlled split-lesion trial. Two test regions similar in size and appearance were randomized to receive treatment or no treatment. These were either 2 scars with a similar appearance located in the same region of the body or 1 scar large enough to demarcate 2 similar test regions. For acne scars on the face, the authors chose 2 areas in which multiple comparable ice-pick scars were situated. Test regions were always separated by a neutral untreated zone of 0.5 cm or more. For randomization, the authors used a digitally generated random list (Graphpad Software Inc., La Jolla, CA) executed by an independent individual not related to the study. Opaque-sealed envelopes containing cards indicating the allocation were numbered and opened in ascending order. The allocation was only revealed to the physician performing the laser treatments. This physician was not included in the pre-treatment or post-treatment assessments, and patients were instructed not to inform the assessor which area had been treated.
Before treatment, scars were mapped with a permanent marker on a flexible transparent sheet using natural landmarks such as moles as reference. A single physician performed 3 laser treatments at 8-week interval with the UltraPulse Encore 10,600-nm CO 2 laser (Lumenis Inc., Santa Clara, CA) using the Deep FX hand piece with a spot diameter of 120 mm and a scan size of 10 mm. The laser procedure was performed in a single pass at 600 Hz and with 15% coverage. Microbeam energy used was 40 mJ on the face and 30 mJ on the body, each lowered with 10 mJ in skin types III and higher. Chosen laser settings were based on available literature on fractional CO 2 laser therapy for facial acne scars and adjusted for scars off the face and in darker skin types. The skin was prepared with chlorhexidine solution and anesthetized by subcutaneous infiltration with lidocaine 2% and epinephrine 1:80,000. Directly after laser treatment, silver sulfadiazine cream was applied under occlusion. Post-treatment care involved thrice daily application of fusidic acid cream during 5 days and the use of a sunscreen (SPF 50).
Measurements
Primary end point was the assessment of the Physician Global Assessment (PhGA) by a blinded physician, not related to the laser treatment. This assessment was performed on site, and scar improvement was scored 0% to 25%, 26% to 50%, 51% to 75%, or 76% to 100%. The presence of adverse effects such as
persistent erythema, hyperpigmentation, hypopigmentation, and scarring was reported by both investigator and patients. To assess pain, a visual analog scale (VAS, scale 0-10) was used.
Secondary end points were the Patient Global Assessment (PGA), scoring no, moderate, good, or excellent improvement of the scar, and the Patient and Observer Scar Assessment Scale (POSAS). 19 This is an evaluation tool in which both patient and assessor score the appearance of the scar on 6 dimensions, on a scale of 1 to 10, with 10 corresponding to the worst possible scar appearance. The melanin and erythema index, using reflectance spectroscopy (DermaSpectrometer; Cortex Technology ApS, Hadsund, Denmark), were used to quantify pigmentation and vascularization. The mean of 3 melanin and erythema index measurements taken from the treated scar, the untreated control, and the normal surrounding skin was calculated at baseline and 6 months after the final treatment.
Digital photographs were taken for documentation with a PowerShot G7 Canon Digital Camera (Canon Inc., Lake Success, NY). Photographs were standardized with respect to magnification, lighting, exposure, and positioning.
Statistical Analysis
All data were collected and transferred to Microsoft Excel. The statistical analysis was performed using Statistical Package for the Social Sciences 19.0 software (SPSS, Chicago, IL). Adverse events were described per item. The Wilcoxon matched-pair test was used for 2 paired comparisons. p values <.05 were considered significant.
Results

Patient Demographics
Twenty-five consecutive patients (36% male and 64% female) visiting the outpatient department with atrophic (52%) or hypertrophic (48%) scars were included in the study and received treatment. Eleven scars had been treated previously. Most patients had scars located on the body (84%), resulting from surgery (52%) or trauma (20%). Only 2 patients had acne scars in the face (Table 1) .
Nine patients received only 1 of 3 laser treatments; 3 of them were withdrawn because of ulcer formation due to the laser treatment, 1 patient discontinued treatment because of illness not related to the treatment, and 5 patients discontinued because of a lack of motivation. A total of 21 patients were seen at 6-month follow-up.
Primary End Points
At 6-month follow-up, according to the PhGA, mild improvement (26%-50%) of the treated side of the scar was found in 7 patients, and in 2 of these patients, the control side had improved equally. Two other scars showed mild improvement of the control side only. One scar had improved with >50%, but this was on both sides of the scar. There was no statistically significant difference (p = .70) between the treated and untreated side on the PhGA score ( Figure 1 ).
Thirty percent of patients experienced mild pain during treatment (median VAS score of 3). Participants reported erythema (87%), crusts (61%), burning sensation (39%), edema (30%), bruising (30%), and vesicles (22%) in the first 5 days after treatment. At 6-month follow-up, persistent erythema (48%), postinflammatory pigmentary changes (24%), and scar formation after ulceration (14%) were observed by the physician as long-term side effects (Figures 2 and 3 ).
Secondary End Points
At 6-month follow-up, the PGA score indicated a significant difference (p = .02) between the treated and untreated control sides. Six patients scored moderate to good improvement on the treated side with no improvement on the control side, 2 patients scored equal improvement on both sides, and the other patients scored no improvement on either side of the scar.
Statistical analysis showed no significant difference in the total POSAS score for both the observer part of the scale (p = .09) and the patient part of the scale A total of 16 female and 9 male patients with a median age of 30 years (IQR, 23-32.5 years) participated in the study. Median scar age was 6 years (IQR, 3.5-15 years).
*Age and scar age in years. †Improvement of the treated side of the scar as measured by physician (PhGA). ‡Dropped out after 1 treatment because of lack of motivation.
xDropped out after 1 treatment because of illness not related to treatment.
A, atrophic; CDLE, chronic discoid lupus erythematosus; F, female; H, hypertrophic; IQR, inter quartile range; M, male; NM, no measurements; X = worsening 0 = no improvement, 1 = mild improvement (26%-50%), 2 = good improvement (51%-75%).
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(p = .19). Also, skin reflectance spectroscopy measurements after 6-month follow-up were not significantly different in the treated and untreated control sides for both the melanin (p = .40) and the erythema (p = .65) index.
Discussion
This is the first randomized controlled trial evaluating the effect of AFLT in the treatment of scars other than atrophic acne scars. Strikingly, none of the treated scars in this trial showed good improvement, and spontaneous improvement of the untreated scars was observed. These findings are not in line with previous randomized controlled trials on AFLT where atrophic acne scars and striae distensae were treated. [16] [17] [18] 20, 21 For AFLT of other types of scars, such as post-traumatic, postsurgical, and burn scars, only anecdotal reports or uncontrolled trials are available. Shumaker and colleagues 5 showed that range of motion and overall skin functionality of traumatic scars of 4 patients improved after 2 to 4 treatments with ablative fractional CO 2 laser. Haedersdal 22 reported a thermal burn scar to improve after a single session of AFLT, comparing 2 different laser settings with no treatment. In a noncontrolled study, Weiss and colleagues treated 15 patients with atrophic postsurgical scars with a fractional CO 2 laser. Six months after the final of 3 laser treatments, skin texture, pigmentation, atrophy, and overall appearance had improved in all scars, as scored by both patients and investigators. 23 Recently, improvement of mature burn scars was reported in 10 patients 2 months after 3 sessions of fractional CO 2 laser treatment, as assessed by both patients and physician using the Vancouver Scar Scale and POSAS assessment. 24 Most of the above-mentioned articles with positive results are uncontrolled studies without blinding of observers. Aside from the difference in study design that may account for less positive outcomes in this study, other factors may have contributed. Location, type, and scar age can be reasons for the poor improvement. The majority of the scars (84%) treated in this study was located on the body. The authors hypothesize that scars located on the face respond better to treatment than scars on the body. [16] [17] [18] 23 Scar type and etiology may also influence the outcome. To date, successful AFLT has been reported in atrophic (acne) scars and burn scars. [16] [17] [18] [22] [23] [24] In this study, Side effects were frequently reported in this study. Of the patients who developed postinflammatory hyperpigmentation, only 1 had a skin type IV and he was treated with lower energy settings. The 3 patients who unexpectedly developed a wound all had skin type II and were treated with 20 to 25 mJ per microbeam. Their scars were located on the torso and extremities. Previously, ulceration was reported after AFLT in the neck, which is known to be a susceptible location for side effects. 26, 27 Recently, Chuang and colleagues 28 reported ulceration after non-ablative fractional laser therapy in 2 patients and suggested that the 1% lidocaine with epinephrine injections were the problem. Other factors that can account for the side effects in this study are all of the above-mentioned factors such as location, type and age of the scar, and laser settings used.
Patients judged that the treated side of their scar had a significantly better appearance than the untreated control side, although none of them scored the improvement as excellent. The positive results scored by one third of the patients are in contrast with the results as scored by the physician. This stresses the importance of controlled studies with blinded observers.
This study is subject to several limitations. First of all, the study population is small. The authors included consecutive patients with divergent etiology, location, and type of scars. This resulted in a very heterogeneous patient population. As the subgroups were so small, comparison of results in scars of different etiology or different location was precluded. Most outcome measures were subjectively scored. Objective measures such as volume measurement or topographic analysis may have added more value to these outcomes. Also, the number of patients who dropped out after the first treatment was higher than expected. Reasons for dropout were the lack of direct clinical improvement and the effort to come to the Postinflammatory hyperpigmentation on the treated side of the scar was still visible at 3-month follow-up but had almost completely resolved at 6-month follow-up (B).
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clinic. The fact that the authors used semifixed energy settings may also be regarded as a limitation. If the authors had used individualized settings, outcomes might have been better with fewer side effects.
In summary, AFLT is not effective in every type of scar encountered in dermatologic practice. Optimization of laser settings in the presence of scar characteristics such as location, age, and etiology may improve outcomes and prevent side effects. More studies with scars of other etiology than acne in higher patient numbers are necessary to identify the type of scars that may benefit from AFLT.
